LATESTSEARCH ⌕
NASDAQ / LIVE COMPANY INTELLIGENCE

Autonomix Medical, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERAMIX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / AMIX COVERAGE

What’s moving Autonomix Medical, Inc. now

Current reporting with the operating signal separated from the noise.

01
Autonomix Medical, Inc.: Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform

Autonomix Medical, Inc.: Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
02
Autonomix Medical, Inc.: Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

Autonomix Medical, Inc.: Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
03
Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules

Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
04
Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

Autonomix Medical, Inc. Announces Release of the Next CEO Corner Segment

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
05
Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System

Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
06
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
07
Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology

Autonomix Medical, Inc. Granted New European Patent for First-in-Class Catheter-Based Technology

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
08
Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

The decision can change Autonomix Medical, Inc.’s market access, costs and competitive freedom.

Watch next: regulator filings, verified operating scope and liability disclosures.
09
Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology

Autonomix Medical, Inc. Announces U.S. Patent Granted Covering the Treatment of Cancerous Tumors and Cancer Related Pain with Company’s Proprietary Catheter-Based Technology

The development tests whether Autonomix Medical, Inc. can turn product investment into adoption, revenue and durable advantage.

Watch next: regulator filings, verified operating scope and liability disclosures.
10
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones

Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones

The story matters when it changes Autonomix Medical, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: regulator filings, verified operating scope and liability disclosures.
PRIMARY DOCUMENTS / SEC EDGAR

Latest AMIX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-02-11 · Period 2025-12-31SEC ↗10-QQuarterly financial reportFiled 2025-11-12 · Period 2025-09-30SEC ↗10-K/AAnnual financial reportFiled 2026-06-15 · Period 2026-03-31SEC ↗8-KMaterial company eventFiled 2026-07-28 · Period 2026-07-28SEC ↗8-KMaterial company eventFiled 2026-07-15 · Period 2026-07-13SEC ↗8-KMaterial company eventFiled 2026-07-10 · Period 2026-07-09SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-09-12 · Period 2025-10-30SEC ↗424B5Official SEC filingFiled 2026-07-31SEC ↗
EARNINGS / QUARTERLY TRACKER

Autonomix Medical, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.